113 related articles for article (PubMed ID: 342393)
41. Granulocyte-macrophage colony-stimulating factor-based melanoma cell vaccines immunize syngeneic and allogeneic recipients via host dendritic cells.
Schneeberger A; Lührs P; Kutil R; Steinlein P; Schild H; Schmidt W; Stingl G
J Immunol; 2003 Nov; 171(10):5180-7. PubMed ID: 14607918
[TBL] [Abstract][Full Text] [Related]
42. Anti-thymocyte autoimmunity in BALB/C mice accompanying immunization to a syngeneic lymphoma.
Baechtel FS; Prager MD
J Immunol; 1977 Jan; 118(1):175-9. PubMed ID: 299754
[TBL] [Abstract][Full Text] [Related]
43. E-rosette forming lymphocytes in thymus, lymph nodes and in tumor from mice bearing syngeneic or allogeneic lymphoma.
Conesa LG; Pasqualini CD; Astaldi G
Boll Ist Sieroter Milan; 1978 Sep; 57(4):458-63. PubMed ID: 737039
[No Abstract] [Full Text] [Related]
44. Cell surface antigen expression on chemically induced murine leukaemias.
Birch JM; Moore M; Craig AW
Br J Cancer; 1975 Jun; 31(6):630-40. PubMed ID: 1174442
[TBL] [Abstract][Full Text] [Related]
45. Allogeneic tumor-syngeneic muscle sandwich grafts: a method for promoting nonspecific growth.
Parks RC
J Natl Cancer Inst; 1976 Jun; 56(6):1281-4. PubMed ID: 994227
[TBL] [Abstract][Full Text] [Related]
46. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
[TBL] [Abstract][Full Text] [Related]
47. Cell-mediated response to a mouse leukemic subline antigenically altered following drug treatment in vivo.
Nicolin A; Bini A; Franco P; Goldin A
Cancer Chemother Rep; 1974; 58(3):325-30. PubMed ID: 4841716
[No Abstract] [Full Text] [Related]
48. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
Ohashi M; Kobayashi A; Hara H; Miura Y; Yoshida K; Kushida M; Ikarashi Y; Mandai M; Kitajima M; Yoshida T; Aoki K
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2208-15. PubMed ID: 16609036
[TBL] [Abstract][Full Text] [Related]
49. Rapid in vivo destruction of semi-syngeneic and allogeneic cells by nonimmunized mice as a consequence of nonidentity at H-2.
Carlson GA; Wegmann TG
J Immunol; 1977 Jun; 118(6):2130-7. PubMed ID: 864255
[No Abstract] [Full Text] [Related]
50. Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space.
Wenkel H; Chen PW; Ksander BR; Streilein JW
Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3202-8. PubMed ID: 10586943
[TBL] [Abstract][Full Text] [Related]
51. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state.
Weinhold KJ; Wheelock EF
Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603
[TBL] [Abstract][Full Text] [Related]
52. Vaccination of leukemic mice with viable drug-altered leukemic cells.
Boerio D; Cavalli M; Marelli O; Veronese F; Nicolin A
Ric Clin Lab; 1978; 8(3):127-33. PubMed ID: 746293
[TBL] [Abstract][Full Text] [Related]
53. Dissociation between cytotoxic activity and delayed hypersensitivity against syngeneic or allogeneic tumor grafts.
Sato M; Nomoto K; Yano Y; Taniguchi K; Takeya K
Gan; 1976 Dec; 67(6):835-47. PubMed ID: 1088135
[TBL] [Abstract][Full Text] [Related]
54. Maternal alloimmune reactions towards the murine conceptus and graft-versus-host reaction (GVHR). I. Priming for anti-paternal GVHR by gestation.
Voisin JE; Monnot P; Voisin GA
J Reprod Immunol; 1986 Jul; 9(2):73-83. PubMed ID: 3746777
[TBL] [Abstract][Full Text] [Related]
55. Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors.
Eisenthal A; Skornick Y; Merimsky O; Hirsch R; Zakut V; Ron I; Chaitchik S
Cancer Immunol Immunother; 1993 Sep; 37(4):233-9. PubMed ID: 8348562
[TBL] [Abstract][Full Text] [Related]
56. Cytogenetic analysis of an immunogenic mutant of the L5178Y lymphoma.
Greenberg AH; Manougian J; Ray M; Goldenberg GJ
Acta Cytol; 1980; 24(3):232-6. PubMed ID: 6773281
[TBL] [Abstract][Full Text] [Related]
57. Cancer immunity after treatment of Ehrlich tumor with diphtheria toxin.
Buzzi S; Buzzi L
Cancer Res; 1974 Dec; 34(12):3481-6. PubMed ID: 4429964
[No Abstract] [Full Text] [Related]
58. Simultaneous development of humoral and cellular tumor-specific immunity against L1210 mouse leukemia.
Kawashima K; Isobe K; Nagase F; Yokochi T; Nagura E; Hasegawa Y; Morishita H; Yamada K; Nakashima I
Leuk Res; 1985; 9(7):935-9. PubMed ID: 4021540
[TBL] [Abstract][Full Text] [Related]
59. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.
Nitta K; Tanaka T; Takeuchi M
Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657
[TBL] [Abstract][Full Text] [Related]
60. Further development of a successful protocol of graft versus leukemia without fatal graft-versus-host disease in AKR mice.
Chester SJ; Esparza AR; Flinton LJ; Simon JD; Kelley RJ; Albala MM
Cancer Res; 1977 Oct; 37(10):3494-6. PubMed ID: 20223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
